{{Rsnum
|rsid=13058338
|Gene=RAC2
|Chromosome=22
|position=37236730
|Orientation=plus
|GMAF=0.1804
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;T)
|geno3=(T;T)
|Gene_s=RAC2
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;T)
| geno3=(T;T)
| CEU | 7.7 | 36.9 | 55.4
| HCB | 0.0 | 13.3 | 86.7
| JPT | 0.0 | 15.6 | 84.4
| YRI | 0.0 | 14.3 | 85.7
| ASW | 0.0 | 0.0 | 0.0
| CHB | 0.0 | 13.3 | 86.7
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs13058338
|Name_s=7508T-->A of RAC2
|Gene_s=RAC2
|Feature=
|Evidence=PubMed ID:16330681
|Annotation=Risk or phenotype-associated allele: A. Phenotype: This SNP was associated with acute cardiotoxicity in response to doxorubicin. Study size: 1697. Study population/ethnicity: Participants of the German non-Hodgkin lymphoma study. Significance metric(s): OR = 2.6; 95% CI, 1.3 to 5.1. Type of association: PD; ADR; TOX.
|Drugs=doxorubicin
|Drug Classes=
|Diseases=Arrhythmias, Cardiac; Cardiomyopathies; Drug Toxicity; Lymphoma, Non-Hodgkin
|Curation Level=Curated
|PharmGKB Accession ID=PA165291817
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs13058338
|overall_frequency_n=18
|overall_frequency_d=128
|overall_frequency=0.140625
|n_genomes=15
|n_genomes_annotated=0
|n_haplomes=16
|n_articles=1
|n_articles_annotated=1
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=23576480
|Title=Association of Anthracycline-Related Cardiac Histological Lesions With NADPH Oxidase Functional Polymorphisms
|OA=1
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}